METABOLIC THERAPEUTICS
Fat Loss
Without
Muscle Loss
5D Therapeutics is developing first-in-class therapies for obesity and type 2 diabetes designed to improve body composition and glucose control without relying on appetite suppression.
THE OPPORTUNITY
The quality of weight loss matters
Current obesity therapies can deliver substantial weight loss, but important needs remain around body composition, tolerability, and incomplete response.
REDUCE FAT
Reduce excess fat while improving body composition.
PRESERVE LEAN MASS
Maintain lean tissue while reducing excess fat.
IMPROVE METABOLISM
Support glucose control through biology distinct from appetite suppression.
5D targets a different biological route to these outcomes
OUR APPROACH
Direct metabolic control
Instead of primarily suppressing appetite, 5D targets metabolic biology directly.
Lead therapeutic approach
Liver-directed RNA medicine
A distinct metabolic strategy with potential for standalone or combination use
SCIENCE
From discovery to therapeutic development
DISCOVERY
Genetic evidence
Mouse phenotype + supportive human genetics
VALIDATION
Pharmacologic validation
Knockdown reproduced key metabolic benefits
TRANSLATION
Lead therapeutic modality selected
~70% liver target knockdown + improved glucose control
Independent genetic and pharmacologic evidence supports therapeutic development of the pathway
COMPANY
Built on deep expertise in metabolic biology and drug development
Richard Gill, PhD
Co-Founder & CEO
7+ years biotech/pharma R&D
10+ years metabolic disease
Diana Kuo, PhD
Co-Founder & CSO
20+ years metabolic biology
Discovered the target's role in type 2 diabetes
STRATEGIC ADVISORS
Robert Barretto, PhD
Drug Development Advisor
Dan Fitzpatrick, PhD
Drug Development Advisor
Gregory Theyel, PhD
Startup Strategy Advisor
Elton Satusky, LLB
IP Strategy Advisor
LET'S CONNECT